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Background
Parotid gland carcinoma is an infrequent tumor, and
series which report on these neoplasms are relatively
scarce in the literature. Our aim is to identify prognostic
factors in parotid gland carcinoma and develop a method
to define the probability of recurrence.
Materials and methods
Patients with parotid gland carcinoma who attended our
institution from January1981 to December 2004 and
completed treatment constitute our study group. Disease-
free survival was calculated using the Kaplan-Meier
method. Logistic regression analysis was used to define
the prognostic factors associated to recurrence.
Results
One-hundred and twenty seven patients were included
(64 male and 63 female). Mean age was 53 years. Mucoep-
idermoid carcinoma was found in 34.6%, adenoid cystic
15.7%, adenocarcinoma 14.3% and acinic cell carcinoma
9.4%. Median disease-free survival was 8.3 years (95% CI
4.3–12.2). Logistic regression analysis confirmed that T
classification, facial nerve palsy, differentiation grade, age
and surgical margins as factors associated to recurrence (p
< 0.00001). Using this model, we defined three postoper-
ative risk groups: high, intermediate and low risk with
recurrence frequency of 71.4%, 43.1% and 8.8%, respec-
tively (p = 0.0001). Five-year disease-free survival for these
groups were 18.7%, 53.9% and 99.9%, respectively (p =
0.00001).
Conclusion
Our study identifies several significant prognostic factors.
Consequently, a prognostic score categorization is pro-
posed, which allows a straightforward calculation of the
recurrence risk for a given case, to define therapeutic strat-
egies, for counseling of patient and to design future trials.
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